The FAST Chip
DIAGNOSTICS TO FIGHT EPIDEMICS AT THEIR SOURCE
RAPIDLY DEPLOYABLE AGAINST EMERGING OUTBREAKS
Zero power required. Autonomous unit. Simple smartphone analysis.Affordable
Injection molding allows mass production of chips at cost 1000 times lower than PCR
Isothermal nucleic acid amplification allows sensitivity comparable to PCR. Quantitative analysis determines concentration of pathogens.
Quick and accurate results allow real-time tracking of outbreak, conveying important information during most crucial times of outbreak.
UC Berkeley invests in mFluiDx
Novemer 2016: mFluiDx completes equity deal with UC Berkeley, making UC Berkeley one of its largest external stakeholders
mFluiDx is accepted into the CITRIS Foundry program
November 2016: mFluiDx is one of 7 startups chosen from an applicant pool of 87 teams to participate in the UC Berkeley-led CITRIS Foundry program.
September 2016: mFluiDx is one of the top 20 companies selected from a global pool of 900 startups to present at TechCrunch Disrupt
IndieBio Demo Day
July 2016: mFluiDx graduates from the IndieBio accelerator program and presents to investors on demo day
mFluiDx joins QB3 network
March 2016: mFluiDx plugs into the resources of QB3.
AS FEATURED IN
David Alland, M.D.
- Chief of Infectious Diseases
Associate Dean of Clinical Research
- Rutgers University
- Created Cepheid MTB/RIF assay
Silvia Pardi, Ph.D. and Gubio Campos Ph.D.
- Professors of Virology
- Federal University of Brazil
- First to Identify Zika virus in Brazil